1.8 cm breast cancer with one positive sentinel node — Z0011 omission, AMAROS swap and SOUND boundary

Stem and task

A 55-year-old woman with a 1.8 cm cancer, clinically node-negative axilla, lumpectomy planned with tangential irradiation and systemic therapy, has one positive sentinel node. She asks for clearance versus no further surgery versus axillary radiotherapy, and whether a friend with a 1.1 cm ultrasound-negative cancer who had no axillary surgery was undertreated. Work through Z0011 eligibility and numbers, the AMAROS swap, and the SOUND boundary.

Model management

Confirm the Z0011 fence before omitting dissection

• She matches the Z0011 population: clinical T1-T2 disease, no palpable adenopathy, 1-2 positive sentinel nodes with lumpectomy plus tangential irradiation and systemic therapy.^[4][5]
• Quote the sampling difference: median 17 nodes with dissection versus 2 with sentinel surgery alone — omission spares a clearance, not a sampling.^[4][6]
• Quote the survival noninferiority: 5-year overall survival 91.8% versus 92.5%, and 10-year overall survival 86.3% versus 83.6% with disease-free survival 80.2% versus 78.2% — no routine dissection on 10-year outcomes.^[4][5]
• Quote the control paradox: 10-year nodal recurrence 0.5% versus 1.5% with locoregional recurrence 6.2% versus 5.3% — excellent regional control despite residual disease.^[6]

Offer the AMAROS swap where axillary treatment is indicated

• Where treatment is required for sentinel-positive cT1-2 disease, dissection and radiotherapy give 10-year axillary recurrence 0.93% versus 1.82% with no OS or DFS difference — control does not choose the modality.^[10]
• Choose on morbidity: lymphoedema 24.5% versus 11.9% favouring radiotherapy — ART preferred for sentinel-positive cT1-2 disease.^[10]

Place the SOUND boundary for the friend

• SOUND enrolled tumours up to 2 cm with negative preoperative axillary ultrasound — the friend's 1.1 cm ultrasound-negative cancer sits inside the trial population.^[11]
• Quote the honesty and the result: 13.7% occult positivity in the sentinel arm, yet 5-year distant disease-free survival 97.7% versus 98.0% — omission noninferior.^[11]
• Apply the caveat: spare surgery only when missing pathology does not affect the postoperative treatment plan — otherwise stage.^[11]

Follow-up and pitfalls

• Do not extend Z0011 to mastectomy, palpable disease, 3 or more positive nodes, or no irradiation — the fence is the result.^[4][5]
• Do not choose AMAROS on control alone — both control excellently, morbidity and second primaries decide.^[10]
• Do not offer SOUND observation when nodal pathology would change systemic or radiation decisions.^[11]